ASCO 2014 Preview and One Micro-Cap of Interest
Research - The American Society of Clinical Oncology (ASCO) annual meeting is right around the corner, and healthcare investors will have a close eye on ASCO for … Continue Reading
Read NowzPremium
What’s Going On With Neptune and its Competitors?
Research - Neptune's (NEPT) IP situation is complicated. Here, we explain what you need to know this year.
Premium: Read NowFinally, Big News From Sarepta Therapeutics
Research - Sarepta Therapeutics (SRPT) will be filing a NDA by the end of this year for eteplirsen. The trade has been good for 150% for those who followed us in early this year.
Premium: Read Now
Longterm Investors Should Be Eyeing Medivation While It’s Out of Favor
Research - – Despite post-earnings selloff, longterm outlook remains intact. MDVN is an attractive part of a core healthcare portfolio. – Off-putting 2014 Xtandi guidance may prove … Continue Reading
Premium: Read Now
Why Sunshine Heart’s Enrollment Issues Are Concerning
Research - Sunshine Heart's (SSH) fourth quarter call was revealing regarding ongoing enrollment problems. Read on to get our take.
Premium: Read Now
Synageva Worth a Look Considering Recent Post-Financing Momentum
Insights - Synageva BioPharma Corp (GEVA) announced the pricing of its secondary offering after the bell on Wednesday. The company priced 2.0 million shares, or 2.3 million including the … Continue Reading
Premium: Read Now
It’s Time to Own Durect – Again
Research - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
Premium: Read Now